Zipalertinib NDA Filed Under FDA Real-Time Review for First-Line EGFR ex20ins NSCLC
CGEM sits 34% above its 52-week low of $7.72.
Summary
Partner Taiho Oncology completed the NDA submission for zipalertinib plus platinum chemotherapy in first-line EGFR exon 20 insertion NSCLC, filed under the FDA's Real-Time Oncology Review program. This closes out the submission Cullinan flagged in its October 1 8-K, when it initiated the filing under RTOR. The application rests on the Phase 3 REZILIENT3 interim analysis, which showed a statistically significant PFS improvement over chemotherapy alone (14.5 vs 8.5 months), data already presented at WCLC in September. Cullinan gets $30M on a second-line U.S. approval and $100M on a first-line approval, meaningful against a roughly $660M market cap. The next hard checkpoint is FDA acceptance of the filing and assignment of a PDUFA target action date; no date has been set yet.
At the time of this announcement, CGEM was trading at $10.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $661.5M. The 52-week trading range was $7.72 to $23.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.